{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:10:49Z","timestamp":1792426249587,"version":"4.5.0"},"reference-count":39,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.<\/jats:p>","DOI":"10.6004\/jnccn.2023.0035","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:43:37Z","timestamp":1689104617000},"page":"694-704","source":"Crossref","is-referenced-by-count":206,"title":["NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, Version 2.2023"],"prefix":"10.6004","volume":"21","author":[{"given":"Al B.","family":"Benson","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Abrams","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Abbott","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Anaya","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Anders","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrakanth","family":"Are","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Bachini","sequence":"additional","affiliation":[{"name":"The Cholangiocarcinoma Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Binder","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Borad","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bowlus","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brown","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Burgoyne","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Castellanos","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhleen","family":"Chahal","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Cloyd","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Covey","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Glazer","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Iyer","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rojymon","family":"Jacob","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Jennings","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Kate","family":"Kelley","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Kim","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Levine","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Palta","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Park","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Raman","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Reddy","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ronnekleiv-Kelly","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Stein","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Turk","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Vauthey","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Yopp","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"McMillian","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Schonfeld","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hochstetler","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS,  Cancer statistics, 2023. CA Cancer J Clin 2023;73:17\u201348."},{"key":"B2","series-title":"Gut Liver","first-page":"298","article-title":"Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study","volume":"3","author":"Park J","year":"2009","unstructured":"Park J, Kim MH, Kim KP,  Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3:298\u2013305."},{"key":"B3","series-title":"NEJM Evid","first-page":"EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh DY","year":"2022","unstructured":"Oh DY, He AR, Qin S,  Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1:EVIDoa2200015."},{"key":"B4","series-title":"Lancet Oncol","first-page":"1560","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo C","year":"2021","unstructured":"Yoo C, Kim KP, Jeong JH,  Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021;22:1560\u20131572."},{"key":"B5","series-title":"JAMA Oncol","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","author":"Hyung J","unstructured":"Hyung J, Kim I, Kim KP,  Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial. JAMA Oncol. Published online March 23, 2023. doi:10.1001\/jamaoncol.2023.0016"},{"key":"B6","series-title":"Cancer","first-page":"1995","article-title":"Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings","volume":"126","author":"Maynard H","year":"2020","unstructured":"Maynard H, Stadler ZK, Berger MF,  Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings. Cancer 2020;126:1995\u20132002."},{"key":"B7","series-title":"JAMA Oncol","first-page":"230","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder NJ","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L,  Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol 2021;7:230\u2013237."},{"key":"B8","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S,  Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731\u2013739."},{"key":"B9","series-title":"Lancet Oncol","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L,  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 2020;21:271\u2013282."},{"key":"B10","series-title":"Nat Med","first-page":"744","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick JK","year":"2019","unstructured":"Sicklick JK, Kato S, Okamura R,  Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 2019;25:744\u2013750."},{"key":"B11","series-title":"Cancer Res","article-title":"CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","volume":"82","author":"Schenker M","year":"2022","unstructured":"Schenker M, Burotto M, Richardet M,  CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Cancer Res 2022;82(12 Suppl):Abstract CT022."},{"key":"B12","series-title":"Int J Cancer","first-page":"2190","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul SA","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M,  Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020;147:2190\u20132198."},{"key":"B13","series-title":"JAMA Oncol","first-page":"888","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim RD","year":"2020","unstructured":"Kim RD, Chung V, Alese OB,  A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020;6:888\u2013894."},{"key":"B14","series-title":"Lancet Oncol","first-page":"1234","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah V","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E,  Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234\u20131243."},{"key":"B15","series-title":"J Clin Oncol","first-page":"3895","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial Subprotocol H","volume":"38","author":"Salama AKS","year":"2020","unstructured":"Salama AKS, Li S, Macrae ER,  Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial Subprotocol H. J Clin Oncol 2020;38:3895\u20133904."},{"key":"B16","series-title":"N Engl J Med","first-page":"228","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal L","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A,  Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388:228\u2013239."},{"key":"B17","series-title":"Cancer Discov","first-page":"326","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman IM","year":"2021","unstructured":"Silverman IM, Hollebecque A, Friboulet L,  Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov 2021;11:326\u2013339."},{"key":"B18","series-title":"Lancet Oncol","first-page":"671","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa GK","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A,  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671\u2013684."},{"key":"B19","series-title":"Lancet Oncol","first-page":"796","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa GK","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM,  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796\u2013807."},{"key":"B20","series-title":"JAMA Oncol","first-page":"1669","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu AX","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM,  Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7:1669\u20131677."},{"key":"B21","series-title":"Cancer Chemother Pharmacol","first-page":"777","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan RK","year":"2009","unstructured":"Ramanathan RK, Belani CP, Singh DA,  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64:777\u2013783."},{"key":"B22","series-title":"Oncology","first-page":"175","article-title":"HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib","volume":"82","author":"Peck J","year":"2012","unstructured":"Peck J, Wei L, Zalupski M,  HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology 2012;82:175\u2013179."},{"key":"B23","series-title":"J Clin Oncol","first-page":"536","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth JD","year":"2018","unstructured":"Hainsworth JD, Meric-Bernstam F, Swanton C,  Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018;36:536\u2013542."},{"key":"B24","series-title":"Nature","first-page":"189","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman DM","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H,  HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018;554:189\u2013194."},{"key":"B25","series-title":"Lancet Oncol","first-page":"1558","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam F","year":"2022","unstructured":"Meric-Bernstam F, Beeram M, Hamilton E,  Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol 2022;23:1558\u20131570."},{"key":"B26","series-title":"Lancet Oncol","first-page":"1290","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle M","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS,  Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22:1290\u20131300."},{"key":"B27","series-title":"J Clin Oncol","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba A","year":"2022","unstructured":"Ohba A, Morizane C, Kawamoto Y,  Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial). J Clin Oncol 2022;40(Suppl):Abstract 4006."},{"key":"B28","series-title":"J Clin Oncol","first-page":"2530","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou SI","year":"2022","unstructured":"Ou SI, J\u00e4nne PA, Leal TA,  First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J Clin Oncol 2022;40:2530\u20132538."},{"key":"B29","series-title":"N Engl J Med","first-page":"1207","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong DS","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH,  KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383:1207\u20131217."},{"key":"B30","series-title":"N Engl J Med","first-page":"2371","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis F","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK,  Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021;384:2371\u20132381."},{"key":"B31","series-title":"Cancer","first-page":"1979","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal L","year":"2017","unstructured":"Goyal L, Zheng H, Yurgelun MB,  A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 2017;123:1979\u20131988."},{"key":"B32","series-title":"Ann Oncol","first-page":"1416","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant S","year":"2014","unstructured":"Pant S, Saleh M, Bendell J,  A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann Oncol 2014;25:1416\u20131421."},{"key":"B33","series-title":"N Engl J Med","first-page":"54","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa GK","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL,  Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54\u201363."},{"key":"B34","series-title":"Ann Transl Med","first-page":"1099","article-title":"Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report","volume":"8","author":"Zhou Y","year":"2020","unstructured":"Zhou Y, Lizaso A, Mao X,  Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report. Ann Transl Med 2020;8:1099."},{"key":"B35","series-title":"Nat Med","first-page":"1640","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Cassier PA, Siena S,  Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat Med 2022;28:1640\u20131645."},{"key":"B36","series-title":"PLoS One","first-page":"e15640","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu TL","year":"2011","unstructured":"Gu TL, Deng X, Huang F,  Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011;6:e15640."},{"key":"B37","series-title":"Am J Surg Pathol","first-page":"1550","article-title":"A novel NIPBL-NACC1 gene fusion is characteristic of the cholangioblastic variant of intrahepatic cholangiocarcinoma","volume":"45","author":"Argani P","year":"2021","unstructured":"Argani P, Palsgrove DN, Anders RA,  A novel NIPBL-NACC1 gene fusion is characteristic of the cholangioblastic variant of intrahepatic cholangiocarcinoma. Am J Surg Pathol 2021;45:1550\u20131560."},{"key":"B38","series-title":"Virchows Arch","first-page":"33","article-title":"Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas","volume":"477","author":"Augustin J","year":"2020","unstructured":"Augustin J, Gabignon C, Scriva A,  Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas. Virchows Arch 2020;477:33\u201345."},{"key":"B39","series-title":"Lancet Oncol","first-page":"1261","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B,  Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 2022;23:1261\u20131273."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/7\/article-p694.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/7\/article-p694.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/7\/article-p694.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:43:38Z","timestamp":1689104618000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/7\/article-p694.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":39,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.0035","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}